CIK 0001716166 · Non-accelerated filer<br>Smaller reporting company
Vivos Therapeutics, Inc.
Sign in to watch- Ticker
- VVOS
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813224056
- Phone
- (866)908-4867
- Business address
- 7921 SOUTHPARK PLAZA,, SUITE 210, LITTLETON, CO, 80120
- Former names
- Vivos BioTechnologies, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-14 | Krammer Anja B Director | Grant or award · Stock Options (Right to Buy) | +12,000 | 17,200 | ||
| 2026-09-14 | Lindsay Mark F. Director | Grant or award · Stock Options (Right to Buy) | +12,000 | 17,200 | ||
| 2026-09-14 | Green Ralph Elias Director | Grant or award · Stock Options (Right to Buy) | +12,000 | 17,200 | ||
| 2026-09-14 | SOKOLOW LEONARD J Director | Grant or award · Stock Options (Right to Buy) | +12,000 | 17,600 | ||
| 2026-09-14 | JOHNSON GREGG C Director | Grant or award · Stock Options (Right to Buy) | +12,000 | 12,000 | ||
| 2026-07-31 | Amman Bradford K. Principal Accounting Officer | Grant or award | +250,000 | $0.41 | $103K | 250,080 |
| 2026-07-31 | Amman Bradford K. Principal Accounting Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | $0.41 | $62K | 326,533 |
| 2026-06-30 | Huntsman Ronald Kirk Chief Executive Officer | Other acquisition | +85,910 | $0.58 | $50K | 85,910 |
| 2026-06-30 | Huntsman Ronald Kirk Chief Executive Officer | Other acquisition · Warrant (Right to Buy) | +85,910 | $0.58 | $50K | 85,910 |
| 2026-06-30 | Skaff Michael C 10% owner | Purchase · Series A Convertible Preferred Stock | +859,166 | $0.58 | $500K | 859,166 |
| 2026-06-30 | Skaff Michael C 10% owner | Purchase · Series A Convertible Preferred Stock | +1,890,164 | $0.58 | $1.1M | 2,749,330 |
| 2026-06-30 | Skaff Michael C 10% owner | Purchase · Common Stock Purchase Warrant | +2,749,330 | $0.58 | $1.6M | 2,749,330 |
| 2026-03-31 | Skaff Michael C 10% owner | Purchase | +1,044,777 | $1.34 | $1.4M | 1,044,777 |
| 2026-03-31 | Skaff Michael C 10% owner | Purchase | +308,848 | $1.34 | $414K | 1,353,625 |
| 2026-03-31 | Skaff Michael C 10% owner | Purchase · Pre-Funded Warrant | +429,957 | $1.34 | $576K | 429,957 |
| 2026-03-31 | Skaff Michael C 10% owner | Purchase · Series A Common Stock Warrant | +1,783,582 | $1.34 | $2.4M | 1,783,582 |
| 2026-03-31 | Skaff Michael C 10% owner | Purchase · Series B Common Stock Warrant | +1,783,582 | $1.34 | $2.4M | 1,783,582 |
| 2024-11-26 | Huntsman Ronald Kirk Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +315,421 | $2.64 | $833K | 364,755 |
| 2024-11-26 | Amman Bradford K. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +149,533 | $2.64 | $395K | 180,533 |
| 2024-06-20 | Thompson Matthew Director | Grant or award · Stock Option (Right to Buy) | +4,000 | $2.38 | $10K | 7,067 |
Page 1 of 4 · 62 trades